Perrigo (PRGO) Non-Current Debt (2013 - 2026)
Perrigo's (PRGO) quarterly Non-Current Debt came in at $3.6 billion in Q1 2026, up 0.83% year-on-year from $3.6 billion in Q1 2025, and little changed on a QoQ basis from $3.6 billion in Q4 2025.
Perrigo (PRGO) Non-Current Debt (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Non-Current Debt data on file, last reported at $3.6 billion in Q1 2026.
- On a quarterly basis, Non-Current Debt rose 0.83% year-over-year to $3.6 billion in Q1 2026; TTM through Mar 2026 was $3.6 billion, a 0.83% increase from a year earlier, with the FY2025 full-year figure at $3.6 billion, up 0.61% from the prior year.
- Non-Current Debt for Q1 2026 stood at $3.6 billion, roughly flat from $3.6 billion in the prior quarter.
- Over the last five years, Non-Current Debt for PRGO reached as high as $4.3 billion in Q3 2024 and fell as low as $3.5 billion in Q2 2022.
- Historically, Non-Current Debt has averaged $3.8 billion across 5 years, with a median of $3.6 billion in 2024.
- Across the five-year window, Non-Current Debt jumped 39.66% in 2022 and slipped 16.34% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $4.1 billion in 2022, then decreased by 10.75% to $3.6 billion in 2023, then decreased by 1.41% to $3.6 billion in 2024, then rose by 0.61% to $3.6 billion in 2025, then gained by 0.49% to $3.6 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $3.6 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 3.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 3.62 Bn |
| Dec 31, 2025 | 3.60 Bn |
| Sep 27, 2025 | 3.61 Bn |
| Jun 28, 2025 | 3.62 Bn |
| Mar 29, 2025 | 3.59 Bn |
| Dec 31, 2024 | 3.58 Bn |
| Sep 28, 2024 | 4.31 Bn |
| Jun 29, 2024 | 3.62 Bn |
| Mar 30, 2024 | 3.62 Bn |
| Dec 31, 2023 | 3.63 Bn |
| Sep 30, 2023 | 4.05 Bn |
| Jul 1, 2023 | 4.06 Bn |
| Apr 1, 2023 | 4.06 Bn |
| Dec 31, 2022 | 4.07 Bn |
| Oct 1, 2022 | 4.08 Bn |
| Jul 2, 2022 | 4.09 Bn |
| Apr 2, 2022 | 3.51 Bn |
| Dec 31, 2021 | 2.92 Bn |
| Oct 2, 2021 | 2.92 Bn |
| Jul 3, 2021 | 2.93 Bn |